TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cell proliferation and apoptosis levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported chronic pain (Intensity) - Children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported chronic pain (Intensity) - Adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic pain reported by caregiver (intensity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First time analgesia request
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Daily pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Regularity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in 25(OH)-D3 levels after supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in uterine artery flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in VHI-10 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Cleansing Level at Colonoscopy by Ottawa Bowel Preparation Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall Cleansing Level at Colonoscopy by Aronchick Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total Volume of Purgatives That Ingested
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Segmental Cleansing Level at Colonoscopy (Right Segment Preparation Failure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Specificity and sensitivity of electrodermal hyporeactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: screening yield
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Subjects With hSBA Titer ≥1:8 Against Serogroup A, C, W and Y
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in blood inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in sputum microbiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in KOOS survey score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum level of MMP-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum level of EPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Patient Pain (O'Leary-Sant Symptom and Problem Indexes)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Subjective Patient Pain (PUF Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Area under the plasma concentration time curve (AUC) of teriparatide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (cmax) of teriparatide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue score for back and leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse events associated with ondansetron
Endpoint domain: Adverse events/effects
Primary endpoint: Prostate-specific antigen (PSA) progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease progression/recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fusion rate of the operated spine segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Subjects Achieving Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Distance of ambulation in the afternoon following surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from surgical stop until three discharge criteria are met
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in minutes spent in moderate to vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Endothelial reperfusion injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Gene expression pattern change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ease of Use of NordiFlex®
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Infection for P. Vivax
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events safety profile
Endpoint domain: Adverse events/effects
Primary endpoint: Type of birth (vaginal birth or Cesarean section)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Aortic Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Mean Quantitative Insulin Sensitivity Check Index (QUICKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Observed PF-06648671 Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Observed Plasma concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time in Plasma (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean number of micturitions per 24 hrs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Glabellar line severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Employment Status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Work Performance (Work Behavior Inventory)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of patients management change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Success Based on IGA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal flora equivalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of depression levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of NAFLD in type 1 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of NAFLD in type 1 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of NAFLD with microvascular and macrovascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association of NAFLD with microvascular and macrovascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to ambulation time during labor
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Formation of CAM deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ease of Mask Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glottic View
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival Without Moderate/Severe Physiologic Bronchopulmonary Dysplasia (BPD)
Endpoint domain: Mortality/survival
Primary endpoint: Survival Without Moderate/Severe Neurodevelopmental Impairment (NDI)
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in Glomerular Filtration Rate (GFR) by 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Resolution of GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average Carbon Dioxide (CO2) Absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Skin Autofluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Remission of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cotinine-confirmed 7-day Point Prevalence Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating microparticles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average Number of Days Without Asthma Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: composite of all-cause mortality or at least one hospital readmission
Endpoint domain: Mortality/survival
Primary endpoint: Plasma levels of TMC278
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24h intragastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Treatment-emergent AEs of Special Interests (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Received Irradiated Haploidentical Cells (IHC) With Disease Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Toxicities Associated With Administration of Irradiated Haploidentical Cells (IHC)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in number of Unmet Needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient or caregiver satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: biomarkers for radiation-induced health effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insomnia severity Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: reduction of systolic blood pressure (mmHg) after spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quadriceps Fibre Size of Type IIa Fibres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Treatment Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Data Completeness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Other Treatments Accessed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient's impression of overall change during treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of pulmonary hypertension-related morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First occurrence of worsening heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First occurrence of need for renal replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Paracetamol uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination index of prediction model for vessel-oriented composite outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fluorescence signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemorrhagic transformation of infarction
Endpoint domain: Adverse events/effects
Primary endpoint: amount of peripheral bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of peripheral bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Retention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decreased frequency of HIV related behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Opioid sparing effects
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hand-foot skin reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Dyadic Relationship
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Degree of Skin Involvement by GVHD Using Two Digital Photography Techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall Response Rate (ORR) Per Independent Review Committee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (ORR) Per Investigator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mucociliary clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient's level of psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient's quality of life related to the Head and Neck condition
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of dose limiting adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: genomic demethylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma ANP level at 1 Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in plasma ANP level at 21 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient-reported severity of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient-reported severity of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient-reported severity of distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Simple Clinical Colitis Activity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Harvey-Bradshaw Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stool biomarkers - degree of intestinal inflammation via Fecal Calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Brief Psychiatric Rating Scale (BPRS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of PICC Line Occlusions
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maturation Value (MV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enrollment and Incidence of Early Transplant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Relapsed-free Survival 6 Months After Transplant
Endpoint domain: Mortality/survival
Primary endpoint: hospital inpatient complications
Endpoint domain: Adverse events/effects
Primary endpoint: F
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonattendance proportion in scheduled outpatient medical appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concentrations of voriconazole in plasma and interstitial space fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Average alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative pancreatic fistula
Endpoint domain: Adverse events/effects
Primary endpoint: TSH Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Blood loss as calculated from change in haematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sodium and potassium consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety of xenotransplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Subjects With Post Procedure Cleansing Level as Measured by the Boston Bowel Preparation Scale (BBPS) Adequate Cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety as Measured by Number of Serious Adverse Events and Major Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Colonoscopy success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HBV DNA PCR negativity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of Change on the ADAS-Cog 11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Change on CDR-SOB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of major depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: In-hospital sepsis related 30-day mortality
Endpoint domain: Mortality/survival
Primary endpoint: Back Pain Change From Baseline at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back Function Change From Baseline by Oswestry Disability Index at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Quality of Life by the EQ-5D Index at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the level of sCD14 in the aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Manual Muscle Testing (MMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Addenbrooke Cognitive Examination (ACE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rapid reversal of warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flavor score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of sensitization and allergy to potato
Endpoint domain: Adverse events/effects
Primary endpoint: Relative Change in Pravastatin Area Under the Plasma Concentration-time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Change in Pravastatin Maximum Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Life quality evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Score in Neuropsychological Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: OSDI (Ocular Surface Disease Index) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6-12 month global clinical outcome (GOS-E)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical severity of specific post-traumatic sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score of pain during BMAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diarrheal episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Glycated Haemoglobin A1c (HbA1c) (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: synovial effusion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Frequency or Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates (CR + CCR + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythropoietic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adherence to the local brain death protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP levels 24 hours postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ke measured by phMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weight reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in MRI result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Magnetic Resonance Imaging (MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dating Violence (DV) Perpetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in General Aggressive Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Attitudes About Relationship Violence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetic properties of infliximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes